Zavegepant: First Approval

Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET™) rece...

Descripción completa

Detalles Bibliográficos
Autor principal: Dhillon, Sohita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209931/
https://www.ncbi.nlm.nih.gov/pubmed/37227596
http://dx.doi.org/10.1007/s40265-023-01885-6
_version_ 1785046970091438080
author Dhillon, Sohita
author_facet Dhillon, Sohita
author_sort Dhillon, Sohita
collection PubMed
description Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article summarizes the milestones in the development of zavegepant leading to this first approval for the acute treatment of migraine with or without aura in adults. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01885-6.
format Online
Article
Text
id pubmed-10209931
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-102099312023-05-26 Zavegepant: First Approval Dhillon, Sohita Drugs AdisInsight Report Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article summarizes the milestones in the development of zavegepant leading to this first approval for the acute treatment of migraine with or without aura in adults. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01885-6. Springer International Publishing 2023-05-25 2023 /pmc/articles/PMC10209931/ /pubmed/37227596 http://dx.doi.org/10.1007/s40265-023-01885-6 Text en © Springer Nature 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Dhillon, Sohita
Zavegepant: First Approval
title Zavegepant: First Approval
title_full Zavegepant: First Approval
title_fullStr Zavegepant: First Approval
title_full_unstemmed Zavegepant: First Approval
title_short Zavegepant: First Approval
title_sort zavegepant: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209931/
https://www.ncbi.nlm.nih.gov/pubmed/37227596
http://dx.doi.org/10.1007/s40265-023-01885-6
work_keys_str_mv AT dhillonsohita zavegepantfirstapproval

Ejemplares similares